Wenwen Du

Wenwen Du

Auto-generated profile, based on publicly available information

Wenwen Du

Department of Pharmacy, China-Japan Friendship Hospital

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2013 in Biomaterials
Verified
Journal Article
Closed access
WDWenwen Du
Wenwen Du
YFYuchen Fan
Yuchen Fan
NZNan Zheng
Nan Zheng
BHBing He
Bing He
LYLan Yuan
Lan Yuan
QZQiang Zhang
Qiang Zhang

6 April 2015 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
WDWenwen Du
Wenwen Du
YFYuchen Fan
Yuchen Fan
BHBing He
Bing He
NZNan Zheng
Nan Zheng
LYLan Yuan
Lan Yuan
QZQiang Zhang
Qiang Zhang

30 December 2020 in Current Drug Metabolism
Verified
Journal Article
Closed access
PDF file
XWXiaoxing Wang
Xiaoxing Wang
WDWenwen Du
Wenwen Du
XZXianglin Zhang
Xianglin Zhang
PLPengmei Li
Pengmei Li
Background: The anti-CD20 antibody rituximab, which promotes the selective depletion of CD20 positive B cells, was the first targeted therapy that was approved for the treatment of B-cell malignancies, and it is now widely prescribed in both malignant and non-malignant, immune-related diseases. However, the cause of its various clinical responses in certain diseases, have not been clearly elucidated. The variabilities in inter-individual pharmacokinetic and the emerging evidence of the relationships between pharmacokinetic and pharmacodynamic may provide a better understanding of this drug.Methods: We searched and summarized the latest published articles on rituximab pharmacokinetic profiles and the pharmacokinetic/pharmacodynamic models in different patient populations, including B-cell malignancies, rheumatoid arthritis, ANCA-associated vasculitis, and glomerular kidney diseases.Results: Most pharmacokinetic data are drawn from clinical studies in oncology clinical practice. Body weight, gender, and antigen-related factors are proven to be the key factors affecting rituximab pharmacokinetics. In addition, the positive exposure-response relations were reported, which provide encouraging evidence for individualized therapies. While in immune disorders, especially in the off-labeled indications, pharmacokinetic studies are quite limited. Compared with that in B-cell malignancies, the differences in the pharmacokinetic parameters may be attributed to the different pathogeneses of diseases, mechanisms of action and dosing strategies. However, the correlation between drug exposure and clinical outcomes remains unclear.Conclusion: Here, we provide an overview of the complexities associated with rituximab pharmacokinetics and pharmacodynamics in different diseases. Although many influencing factors need to be verified in future studies, a better understanding of the relationships between pharmacokinetic and pharmacodynamic may assist in optimizing rituximab clinical practice.

29 May 2019 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
HTHaicheng Tang
Haicheng Tang
WDWenwen Du
Wenwen Du
YJYongqian Jiang
Yongqian Jiang
HLHongmiao Li
Hongmiao Li
HBHongjian Bo
Hongjian Bo
SSShu Song
Shu Song

1 January 2026 in Journal of Clinical Pharmacy and Therapeutics
Verified
Journal Article
Open access
DZDan Zhang
Dan Zhang
WDWenwen Du
Wenwen Du
WQWei Qin
Wei Qin
BLBo Li
Bo Li
PLPengmei Li
Pengmei Li
WCWenqian Chen
Wenqian Chen
Background: Voriconazole (VCZ) served as primary therapy for invasive aspergillosis in lung transplant recipients. However, VCZ‐induced hepatotoxicity emerged as a frequent adverse effect that critically compromised postoperative management and complication prevention in this vulnerable population. Methods: We performed population pharmacokinetic/pharmacodynamic (PK/PD) modeling using nonlinear mixed‐effects methodology. The analysis included a one‐compartment PK model with alkaline phosphatase (ALP) as the primary hepatotoxicity biomarker. Monte Carlo simulations assessed the effects of dosing regimens on ALP dynamics across various covariate scenarios. Results: The final PK/PD model indicated an apparent systemic clearance of 3.09 L/h and a central volume of 80.31 L. The exposure–response relationship was described using an indirect response model, with the pharmacological effect linked to increases in ALP levels. The maximum drug effect (E max ) was 188.78. The rate constant for psoriatic plaque production (K in ) was 0.31/day, while the rate for plaque loss (K out ) was 0.53/day. Creatinine clearance (CrCL) was identified as a key covariate for apparent clearance, while weight and tacrolimus (TAC) trough level were significant for Emax. The average probability of target attainment for optimized regimens reached 50.2% across all covariate combinations. Clinical simulations identified 100 mg twice daily (bid) as the optimal maintenance dose for hepatotoxicity prevention. Weight‐based dose reduction was recommended for recipients below 50 kg, with stringent therapeutic drug monitoring of TAC concentrations. Conclusion: Our population PK/PD model provides clinically actionable guidance for VCZ dose optimization, particularly for underweight lung transplant recipients on maintenance therapy. The model effectively predicts and prevents VCZ‐induced hepatotoxicity while maintaining therapeutic efficacy.

20 September 2024 in Renal Failure
Verified
Journal Article
Open access
WDWenwen Du
Wenwen Du
DZDan Zhang
Dan Zhang
WCWenqian Chen
Wenqian Chen
WCWenhui Chen
Wenhui Chen
PLPengmei Li
Pengmei Li
XWXiaoxing Wang
Xiaoxing Wang
The purpose of this study was to investigate the correlation between different subtypes of acute kidney injury (AKI) and clinical outcomes following lung transplantation (LTx) and to identify a reliable indicator for predicting poor prognosis in the LTx population. We retrospectively analyzed the clinical data of 279 LTx patients from August 2016 to March 2023. The AKI subtypes included AKI, persistent AKI on Day 7 (P7-AKI) and Day 14 (P14-AKI) after LTx, and AKI stages. The correlations of these factors with respiratory outcomes, mortality at 90 days, mortality at 1 year and data finalization were assessed, and the risk factors for the selected AKI subtypes were evaluated. AKI occurred in 215 patients (77.1%), with 129 (46.2%) experiencing P7-AKI and 95 (34.1%) experiencing P14-AKI. P7-AKI was associated with more respiratory and mortality outcomes than were AKI and AKI stages, and P7-AKI surpassed P14-AKI in terms of a shorter diagnostic time. After adjusting for age, sex, BMI, type of transplant, transplant diagnosis and comorbidities, P7-AKI independently correlated with increased mortality risk at 90 days [HR 12.312 (95% CI: 2.839-53.402)], 1 year [HR 3.847 (95% CI: 1.840-8.044)], and data finalization [HR 2.010 (95% CI: 1.331-3.033)]. Five variables were identified as independent predictors for P7-AKI, including preoperative body mass index, prothrombin activity, hemoglobin and serum creatinine, and intraoperative colloid administration. P7-AKI has been identified as a reliable indicator for predicting adverse outcomes in LTx patients, which may assist healthcare professionals in identifying high-risk individuals.